3D Gens has reached a significant research milestone: the company's 2025 bioprinter project has officially received both grant funding and ethics approval. For a biomedical research initiative, these two approvals together represent the green light to move from concept to active research — a moment that signals real momentum for 3D Gens' bioprinting programme.
Why Both Approvals Matter
Grant funding and ethics approval are separate but equally essential gates for biomedical research. A grant provides the financial resources to conduct the work; ethics approval confirms that the research protocol meets the standards required for responsible conduct involving biological materials or human-adjacent applications.
Receiving both simultaneously — or in close succession — removes the uncertainty that can stall research programmes and allows the team to move forward with confidence and clarity.
3D Gens' Bioprinting Journey
3D Gens' investment in bioprinting is a natural extension of its medical manufacturing capabilities. The company already produces patient-specific implants from metal and polymer; bioprinting extends this into the realm of biological scaffolds and tissue-engineering applications, where the "materials" include living cells and biologically active compounds.
The GENSx170, 3D Gens' homegrown bioprinter, has already been deployed in research settings at universities including USM. The 2025 research project builds on this platform, pushing the boundaries of what can be achieved with domestically developed bioprinting technology.
Looking Ahead
With funding secured and ethics clearance in hand, the 2025 bioprinter project enters its active research phase. Outcomes from this work will contribute to Malaysia's growing body of knowledge in bioprinting — and potentially to the next generation of 3D Gens' medical manufacturing capabilities.